Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T04:17:49.463Z Has data issue: false hasContentIssue false
  • English
  • Français

Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders

Published online by Cambridge University Press:  09 July 2009

H. M. Van Praag ,
J. Korf ,
J. P. W. F. Lakke  and
T. Schut
H. M. Van Praag
Affiliation:
Department of Biological Psychiatry and the Department of Neurology, State University of Groningen, The Netherlands
J. Korf
Affiliation:
Department of Biological Psychiatry and the Department of Neurology, State University of Groningen, The Netherlands
J. P. W. F. Lakke
Affiliation:
Department of Biological Psychiatry and the Department of Neurology, State University of Groningen, The Netherlands
T. Schut
Affiliation:
Department of Biological Psychiatry and the Department of Neurology, State University of Groningen, The Netherlands
Get access Rights & Permissions [Opens in a new window]

Synopsis

The probenecid technique was used in a study of the central dopamine DA metabolism in patients with depressions, psychotic disorders, and Parkinson's disease. The disturbances found were neither nosologically nor syndromally specific, but appeared to be symptom-specific. Decreased DA turnover was associated with hypomotility, and increased DA turnover with hypermotility. Decreased DA turnover was probably related aetiologically to the hypomotility: the symptoms subsided after replenishment of the DA deficiency. The relation between increased DA turnover and hypermotility is still under investigation. In view of the findings obtained, a plea is made for the development of a functional psychopathology, in which psychiatric syndromes are ‘dissected’ into their constituent psychological dysfunctions. This development is expected to stimulate human brain and behaviour research. It can be achieved only by intensive collaboration between psychiatrists and experimental psychologists.

Type
Original Article
Information
Psychological Medicine , Volume 5 , Issue 2 , May 1975 , pp. 138 - 146
Copyright
Copyright © Cambridge University Press 1975

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andén, N. E., Corrodi, H., and Fuxe, K. (1972). Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine-β-hydroxylase inhibitors. Journal of Pharmacy and Pharmacology, 24, 177–182.CrossRefGoogle Scholar
Angrist, B., Sathanathan, G., and Gershon, S. (1973). Behavioral effects of L-dopa in schizophrenic patients. Psychopharmacologia, 31, 1–13.CrossRefGoogle ScholarPubMed
Bowers, M. B. Jr (1972). Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: reliability and interpretation of cerebrospinal fluid acid monoamine metabolites measures. Neuropharmacology, 11, 101–111.CrossRefGoogle ScholarPubMed
Bowers, M. B. Jr, and Van Woert, M. H. (1972). The probenecid test in Parkinson's disease. Lancet, 2, 926–927.CrossRefGoogle ScholarPubMed
Goodwin, F. K., Murphy, D. L., Brodie, H. K. H., and Bunney, W. E. Jr (1970.) L-dopa, catecholamines, and behaviour: a clinical and biochemical study in depressed patients. Biological Psychiatry, 2, 341–366.Google ScholarPubMed
Goodwin, F. K. (1971). Psychiatric side effects of levodopa in man. Journal of the American Medical Association, 218, 1915–1920.CrossRefGoogle ScholarPubMed
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.CrossRefGoogle ScholarPubMed
Jéqiuer, E., and Dufresne, J. J. (1972). Biochemical investigations in patients with Parkinson's disease treated with L-dopa. Neurology, 22, 15–21.CrossRefGoogle Scholar
Korf, J., and Praag, H. M. van. (1971). Amine metabolism in the human brain: further evaluation of the probenecid test. Brain Research, 35, 221–230.CrossRefGoogle ScholarPubMed
Korf, J., Ottema, S., and Veen, I. van der (1971). Fluorometric determination of homovanillic acid in biologicalmaterial after isolation on Sephadex G-10. Analytical Biochemistry, 40, 187–191.CrossRefGoogle Scholar
Korf, J., Praag, H. M. van, Schut, D., Nienhuis, R. J., Lakke, J. P. W. F. (1974). Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-dopa therapy. European Neurology, 12, 340–350.CrossRefGoogle ScholarPubMed
Lakke, J. P. W. F., Korf, J., Praag, H. M. van, and Schut, T. (1972). The predictive value of the probenecid test for the effect of L-dopa therapy in Parkinson's disease. Nature New Biology, 236, 208–209.CrossRefGoogle ScholarPubMed
Lowe, G. R. (1973). The phenomenology of hallucinations as an aid to differential diagnosis. British Journal of Psychiatry, 123, 621–633.CrossRefGoogle ScholarPubMed
Neff, N. H., Tozer, T. N., and Brodie, B. B. (1967). Application of steady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma. Journal of Pharmacology and Experimental Therapeutics, 158, 214–218.Google Scholar
Nybäck, H., and Sedvall, G. (1970). Further studies on the accumulation and disappearance of catecholamines formed from tyrosine-14 C in mouse brain. Effect of some phenothiazine analogues. European Journal of Pharmacology, 10, 193–205.CrossRefGoogle Scholar
Olsson, R., and Roos, B.-E. (1968). Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease. Nature, 219, 502–503.CrossRefGoogle ScholarPubMed
Praag, H. M. van, Uleman, A. M., and Spitz, J. C. (1965). The vital syndrome interview. A structured standard interview of the vital depressive symptom complex. Psychiatria, Neurologia, Neurochirurgia, 68, 329–346.Google ScholarPubMed
Praag, H. M. van, Korf, J., and Puite, J. (1970). 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature, 225, 1259–1260.CrossRefGoogle ScholarPubMed
Praag, H. M. van, and Korf, J. (1971). Retarded depression and the dopamine metabolism. Psychopharmacologia, 19, 199–203.CrossRefGoogle Scholar
Praag, H. M. van (1972). Biological Psychiatry in perspective: The dangers of sectarianism in psychiatry. Comprehensive Psychiatry, 13, 401–410.CrossRefGoogle ScholarPubMed
Praag, H. M. van, Korf, J., and Schut, T. (1973). Cerebral monoamines and depression. An investigation with the Probenecid technique. Archives of General Psychiatry, 28, 827–831.CrossRefGoogle ScholarPubMed
Praag, H. M. van (1973.) Psychotropic drugs as catalysts of scientific research. Psychiatria, Neurologia, Neurochirurgia, 76, 159–161.Google ScholarPubMed
Praag, H. M. van (1974a). Towards a biochemical typology of depressions? Pharmakopsychiatrie, 7, 281–292.CrossRefGoogle Scholar
Praag, H. M. van (1974b). New development in human psychopharmacology. Comprehensive Psychiatry. 15, 389–401.CrossRefGoogle ScholarPubMed
Snyder, S. H. (1972). Catecholamines in the brain as mediators of amphetamine psychosis. Archives of General Psychiatry, 27, 169–179.CrossRefGoogle ScholarPubMed
Tamarkin, N. R., Goodwin, F. K., and Axelrod, J. (1970). Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Life Sciences, Pt. 1, 9, 1397–1408.CrossRefGoogle ScholarPubMed
Venables, P. H. (1957). A short scale for rating “activity-withdrawal” in schizophrenics. Journal of Mental Science, 103, 197–199.CrossRefGoogle Scholar
Zung, W. W. K. (1965). A self-rating depression scale. Archives of General Psychiatry, 12, 63–70.CrossRefGoogle ScholarPubMed